Apixaban in patients with atrial fibrillation.

N

NEJM

@NEJM · X

Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.co/sx5FtVvSk5

EJ

European Society of Cardiology Journals

@ESC_Journals · X

Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with Atrial Fibrillation and Peripheral Artery Disease - https://t.co/HcLJEZcF8s #EHJPharmacotherapy https://t.co/BCyd7vmjNF

AM

Ahmed Bennis MD

@drbennisahmed · X

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use OCEANIC-AF Randomized Clinical Trial OAC-naive patients had a significantly smaller increase in stroke or systemic embolism with asundexian https://t.co/55ftteOfim https://t.co/L8xkzlVhmC

AJ

Anesthesiology Journals

@_Anesthesiology · X

Direct-acting oral anticoagulants prevent stroke in patients with atrial fibrillation but carry the risk of bleeding. Read a summary of "Asundexian versus apixaban in patients with atrial fibrillation" in the May 2025 SM&A: https://t.co/gy6chMvLvn https://t.co/ifXTnOk1d5

MS

Musa A. Sharkawi

@MusaSharkawi · X

@willsuh76 Based on the AVERROES trial, I’d go with full dose Apixiban (unless pt has 2/3 of Cr >1.5, age >80 or weight<60 kg then 2.5 mg BID). In AVERROES, aspirin and apixiban had the same rate of bleeding. https://t.co/lHT35p62Dy

AM

Ahmed Bennis MD

@drbennisahmed · X

Asundexian versus Apixaban in Patients with Atrial Fibrillation treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment with apixaban https://t.co/69UQWJr6rc https://t.co/Ny1jTpw102

TH

Tom Hsiung

@TomHsiung · X

Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease https://t.co/yKRPx6fPhR

JE

Juan Carlos Elizalde:.

@JuanElizalde777 · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

NP

Nikos Pyrpyris

@pyrpyris · X

RT @MattiaGalli10: Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease…

AB

Abhijit Biswas

@Abhijit78446070 · X

RT @MattiaGalli10: Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease…

FG

Felice Gragnano

@FeliceGragnano · X

RT @MattiaGalli10: Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease…

MG

Mattia Galli

@MattiaGalli10 · X

Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease @EditorEHJCVP @FeliceGragnano @pyrpyris @ESC_Journals https://t.co/8cb6WJnJIr

OL

Osama Louis

@OsamaLouis5 · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

TH

Tom Hsiung

@TomHsiung · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

DJ

Dr.AMiT JAiSWAL

@aadvikmedics · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

MQ

mahmoud_quandil

@mahmoud_quandil · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

RM

Riccardo Osti MD

@RashidLeDocteur · X

Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease https://t.co/EzBTkMXw1q #ESC2025

J

jabar

@turilrh · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

PS

Parham Sadeghipour

@psadeghipour · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

AC

Alejandro I. Pérez Cabeza

@alejandroipc2 · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

M

maldinilin

@maldinilin · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

LL

Lê Văn Lắm

@levanlam95 · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

NR

Natsir Ramadhan

@natsiradhan · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

HR

Hany Ragy

@Hragy · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

SN

Syed Ali Naqvi

@SyedYNaqvi1 · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

PM

Pascal Meier,MD

@DrPascalMeier · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

JB

John P Erwin III MD MBA MACC (#BigPoppy )

@HeartOTXHeartMD · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

FH

Felipe Hernández

@pipecardio · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

XR

Xacobe Flores Rios

@xacobeflores · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

TF

Tomohiro Fujisaki

@TomohiroFujisa2 · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

TF

Tomohiro Fujisaki

@TomohiroFujisa2 · X

DOACの比較研究が出てきています。アピキサバンの安全性が高い結果。Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease https://t.co/4NXOoOjSBY

AF

Andres Felipe Florez

@Andresffmed · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

EJ

EOLO MORANDI JR.

@eolojr · X

RT @ESC_Journals: Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with A…

EJ

European Society of Cardiology Journals

@ESC_Journals · X

Simultaneous publication during #ESCCongress Effectiveness and safety of Rivaroxaban versus Apixaban in patients with Atrial Fibrillation and Peripheral Artery Disease - https://t.co/HcLJEZcF8s #EHJPharmacotherapy https://t.co/BCyd7vmjNF

M

mocchi

@mocchi_ym · X

RT @drbennisahmed: Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use OCEANIC-AF Randomi…

AM

Ahmed Bennis MD

@drbennisahmed · X

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use OCEANIC-AF Randomized Clinical Trial OAC-naive patients had a significantly smaller increase in stroke or systemic embolism with asundexian https://t.co/55ftteOfim https://t.co/L8xkzlVhmC

Iإ

Iyas إياس

@iyas_daghlas · X

I've been skeptical of this view based on findings from AVERROES (which didn't show higher risk of bleeding w/ apix vs ASA), though data were too imprecise to permit strong inferences. https://t.co/TIGmxzVJTF

WD

waqar dahri

@Dahri85Waqar · X

RT @_Anesthesiology: Direct-acting oral anticoagulants prevent stroke in patients with atrial fibrillation but carry the risk of bleeding.…

AJ

Anesthesiology Journals

@_Anesthesiology · X

Direct-acting oral anticoagulants prevent stroke in patients with atrial fibrillation but carry the risk of bleeding. Read a summary of "Asundexian versus apixaban in patients with atrial fibrillation" in the May 2025 SM&A: https://t.co/gy6chMvLvn https://t.co/ifXTnOk1d5

TL

the paper link

@the_paper_link · X

Trend up+11: Benkhoff M, ..., Polzin A (N Engl J Med) __Asundexian versus Apixaban in Patients with Atrial Fibrillation__ https://t.co/eLy7S3mLvU

M

Marko

@Markotelomerase · X

RT @SeeFisch: YOU WILL HEAR OF A FACTOR XI INHIBITOR FOR A FIB. WE do NOT THINK THIS WILL BE A GOOD DRUG Asundexian versus Apixaban in Pat…

CF

Conrad Fischer

@SeeFisch · X

YOU WILL HEAR OF A FACTOR XI INHIBITOR FOR A FIB. WE do NOT THINK THIS WILL BE A GOOD DRUG Asundexian versus Apixaban in Patients with Atrial Fibrillation | New England Journal of Medicine https://t.co/CSuKLC2JpI

DG

Diana G

@DianaGM_13 · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

J

Jose

@Jose82044721745 · X

RT @Montecoya: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/lRcxiUbDhh

JG

JORGE GARCIA

@GeorgusCayo · X

RT @Montecoya: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/lRcxiUbDhh

SC

Sergio Calleja

@Montecoya · X

Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/lRcxiUbDhh

EH

Eman Hassan

@Eman__Hassan__ · X

RT @DFCapodanno: The OCEANIC-AF trial, comparing asundexian to apixaban in patients with atrial fibrillation was halted early due to a sign…

PF

Pao-Hsien, Chu M.D., FCCP, FACC, FESC, FAPSC

@PoChu3 · X

Asundexian versus Apixaban in Patients with Atrial Fibrillation | New England Journal of Medicine https://t.co/jiQlivlRIv

AS

Ariel Santos

@traumamd1 · X

Asundexian - Factor XIa inhibitor versus Apixaban in Patients with Atrial Fibrillation | @NEJM Asundexian is associated with higher stroke or embolism vs. Apixaban @TTUHSCSurgery https://t.co/lCrbiFrGE0

TH

The Heart

@ZHeart11768530 · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

せ

せいや

@kusuriawanosuke · X

次世代のDOACとして期待されたアスンデキシアンとアピキサバンとの心房細動患者に対する比較（非劣性） Asundexian versus Apixaban in Patients with Atrial Fibrillation | New England Journal of Medicine https://t.co/kAfXGviR9x

MR

Massimo Romano

@dottmasroman · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

JS

Jakob Stensballe

@J_Stensballe · X

RT @bryanacotton1: XI vs X inhibitor RCT:

TF

Teba González-Ferrero

@tebagf · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

RC

Rodrigo Nunes Cal

@CalZole · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

US

Uriel Suárez

@UsuarezMD · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

AH

Aghiles Hamroun

@AghilesHamroun · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

A

AngryPhDstudent❗️❗️❗️

@ONNESHA092 · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

GB

Giuseppe Bellelli

@GiuseppeBellel1 · X

Asundexian versus Apixaban in Patients with Atrial Fibrillation | New England Journal of Medicine https://t.co/fJJ4WOXLdx

RS

Rita Swartz

@buckleyswartz · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

AM

Ahmed Bennis MD

@drbennisahmed · X

Asundexian versus Apixaban in Patients with Atrial Fibrillation treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment with apixaban https://t.co/69UQWJr6rc https://t.co/Ny1jTpw102

DB

Dr. Joshuan J. Barboza

@joshuanbarbozam · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

BC

Bryan Cotton

@bryanacotton1 · X

XI vs X inhibitor RCT:

CD

Carmelo Espinosa M.D.

@carmelografo · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

แว

แม่เรียกล้างจานแล้ว

@CtherP3 · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

Nว

Neo_ID เป็นพ่อมดสัตว์จิ๋ว

@1IDCNMI · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

MM

Manoj Mayogi Mishra

@mayogisense · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

JM

Jan Hartmann, MD

@JanHartmannMD · X

Asundexian versus Apixaban in Patients with Atrial Fibrillation | New England Journal of Medicine https://t.co/M4gpdS4xDI

HA

Hiroshi Akazawa

@AkazawaHiroshi · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

SA

Santhosh Ambika

@RenoHemonc · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

EA

Elena Zapata-Arriaza

@ELeNaZapS · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.c…

N

NEJM

@NEJM · X

Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation https://t.co/dZPaihNNp6 #Cardiology https://t.co/sx5FtVvSk5

EC

ESC WG Thrombosis Chairperson

@ESCWGThrombosis · X

Explore the latest WG on #Thrombosis Paper of the Month!Our commentary dives into the OCEANIC-AF trial, comparing #asundexian and apixaban in #atrialFibrillation patients. Insights on efficacy, safety, and future directions await.

AS

Albert Kagina Sinyigaya

@DrSinyigaya · X

RT @DrSinyigaya: Comparison of Watchman procedure with new oral anti-coagulants (Apixaban)—in patients with atrial fibrillation: A network…

FV

Felix Valencia

@FelixValencia10 · X

How happen with the results of AVERROES trial? It never occurred? Can we forget it? https://t.co/GHb2MhMtyn https://t.co/6SnPKjaYXp

AU

AtrialFib_US

@AtrialFib_US · X

RT @ValleAlfonso:

JM

Jahir Rodríguez - Rivera MD

@j_rdzrivera · X

RT @ValleAlfonso:

LP

Luis Jara-Palomares

@luistrombo · X

RT @juanjolopezn: Asundexian versus Apixaban in Patients with Atrial Fibrillation #atrialfibrillation #asundexian #apixaban @NEJM https://t…

JN

Juan José López Núñez

@juanjolopezn · X

Asundexian versus Apixaban in Patients with Atrial Fibrillation #atrialfibrillation #asundexian #apixaban @NEJM https://t.co/L8NF09YWRx

SS

Shreya-S

@shreya1179 · X

RT @dralexvakili: Honored to have participated as a principal site investigator, researcher and clinical research site in the Oceanic -AF A…

S

.salma

@Salmammn1990 · X

RT @DrDamluji: Asundexian versus Apixaban in Patients with Atrial Fibrillation: @NEJM

DM

Dr. B. Alex Vakili MD

@dralexvakili · X

Honored to have participated as a principal site investigator, researcher and clinical research site in the Oceanic -AF Asundexian versus Apixaban in Patients with Atrial Fibrillation clinical trial published in the NEJM September 1 issue. Unfortunately, the data did not pan out

CC

Canadian VIGOUR Centre

@CVC_UAlberta · X

RT @NEJM:

EM

Eduardo Martínez

@Eduardomtzv55 · X

RT @ValleAlfonso:

NH

Nada Hassib

@NadaHassib1 · X

Asundexian versus Apixaban in Patients with Atrial Fibrillation | New England Journal of Medicine https://t.co/BmnRTR0LsR

PK

Professor M Z Khalil

@mzkhalil · X

Asundexian versus Apixaban in Patients with Atrial Fibrillation | NEJM #asundexian didn’t do the job..

AF

Andres Felipe Florez

@Andresffmed · X

RT @NEJM: Original Article: Asundexian versus Apixaban in Patients with Atrial Fibrillation (OCEANIC-AF) https://t.co/dZPaihNNp6 #ESCardi…

AF

Andres Felipe Florez

@Andresffmed · X

RT @DFCapodanno: The OCEANIC-AF trial, comparing asundexian to apixaban in patients with atrial fibrillation was halted early due to a sign…

LC

Life Science Journal Content

@lsn_jc · X

Asundexian versus Apixaban in Patients with Atrial Fibrillation #science #publication #research #journal https://t.co/tpM6OqcGuU

JM

Jorge Salazar M

@SalazarMJA · X

RT @NEJM:

JA

Jason Andrade

@DrJasonAndrade · X

@Ricky_Turgeon You have data on apixaban vs Asa in af (https://t.co/UfgSKh1dY0) though they had to be OAC ineligible…

L

lal0155

@lal0155 · X

RT @pinacol: デザインを解説した論文（https://t.co/o9i7Z3jbuy）を読むに、ARTESIA試験でアスピリンを対照にしたのは、この試験（https://t.co/dRuJpX0O29）で心房細動でアピキサバンvsアスピリンはこういう結果だったけど、…

P

pinacol

@pinacol · X

デザインを解説した論文（https://t.co/o9i7Z3jbuy）を読むに、ARTESIA試験でアスピリンを対照にしたのは、この試験（https://t.co/dRuJpX0O29）で心房細動でアピキサバンvsアスピリンはこういう結果だったけど、AHREではどうなんだろうという疑問があったからかな。

JK

Jun Kim

@mdjunkim · X

Apixaban does not increase bleeding compared with ASA in warfarin intolerable AF patients. Apixaban increase bleeding compared with ASA in subclinical AF. https://t.co/BjDTornsDp

SM

Seba GZ, MD, MSc

@sebagz1 · X

@SantasEnrique @secardiologia @SVCardio @clinica_sec Estos resultados van en contra de lo que mostró AVERROES, con 10 veces mas

RB

Ryan Caputo, PharmD, BCCP

@RyanCaputo1 · X

@MutazAlkalbani Never aspirin based on the AVERROES trial. Less effective at preventing stroke with the same bleeding risk as apixaban. https://t.co/tdwClZtsZj

MK

Michal Krawczyk

@4mmk36 · X

@MedFactChecks @TotoMynell @TheSGEM @stephanamayer @ravigarg415 @Hamishmcmack "High risk population"? Based on what evidence? The risk of ICH with apixaban is likely no different from that of aspirin. https://t.co/YfvYBJZODL

EW

Ethan J. Weiss

@ethanjweiss · X

@matthewherper @bradloncar @BentheFidler The article, says they enrolled people with stroke but not specifically AF. If I were developing a drug in this space these days, I'd spend time studying AVVEROES but focusing on patients unwilling or unable to take DOACs. Much harder obviously today https://t.co/WfXuAspCNG

ME

Magnus Esbjornsson

@MagEsbjornsson · X

@spraguepond The AVERROES trial showed that the risk of serious bleeding complications is equal with apixaban compared to aspirin, and provides much greater protection against stroke. https://t.co/YpiIeFtLGY The issue is - why switch to aspirin instead of reducing the dose of Eliquis as rec?

AM

Ahmad Masri

@MasriAhmadMD · X

Will take a long time to adjust the way we think about aspirin! 10 years haven't moved the needle much https://t.co/56mkzxNSW3 #CardioTwitter https://t.co/H6dPnfkfKx

AM

Ahmad Masri

@MasriAhmadMD · X

Finally, don't forget AVERROES findings where ASA was compared to apixaban https://t.co/56mkzxNSW3

CT

Caio de Assis Moura Tavares

@caiodeamtavares · X

5/15 More contemporary data comparing aspirin x anticoagulation (BAFTA – Warf x Aspirin (https://t.co/LGPV1rlkd4) and AVERROES – Apixaban x Aspirin (https://t.co/tyxKtLMGPq)) saw similar bleeding and increased rates of embolism with Aspirin. So less is not more, in this case

AM

Ahmad Masri

@MasriAhmadMD · X

@cardskrish Excellent point - will be a discussion with the patient but if you follow prior apixaban vs aspirin, it is likely to be similar https://t.co/PGZdmbYiaM Situation is harder when patients can only afford warfarin

TE

Trisha Elliott

@Trisha_the_doc · X

RT @DrDerekConnolly: @Trisha_the_doc @doc_hnaqvi and we know that aspirin has no role in older patients with NVAF after studies like BAFTA…

PC

Prof Derek Connolly

@DrDerekConnolly · X

@Trisha_the_doc @doc_hnaqvi and we know that aspirin has no role in older patients with NVAF after studies like BAFTA and Averroes https://t.co/SMA7rh6xV7

MS

Musa A. Sharkawi

@MusaSharkawi · X

@willsuh76 Based on the AVERROES trial, I’d go with full dose Apixiban (unless pt has 2/3 of Cr >1.5, age >80 or weight<60 kg then 2.5 mg BID). In AVERROES, aspirin and apixiban had the same rate of bleeding. https://t.co/lHT35p62Dy

SG

Stormi Gale

@stormigale · X

@bmorecardiology @drjohnm @ATRIUMRx @MKIttlesonMD There is also similar data that suggests ASA does not decrease bleed risk in AF compared to apixaban: https://t.co/RidYMhmJMK

AM

Ahmad Masri

@MasriAhmadMD · X

@TYWangMD Havent seen the trial results. But based on this: https://t.co/PGZdmbYiaM Would always go with DOAC over a procedure, a shaky pathophys, a nidus for thrombi, and dapt

VV

Vass Vassiliou

@vass_vassiliou · X

@savodoc @drstephenpettit @drjasondungu @JGrapsa @Apple ...bleeding risk not different between aspirin and a NOAC, so in this case I would recommend a NOAC. @venkmurthy will have views about Apple Watch - but at present I wouldn’t recommend it for this patient... https://t.co/wEpMehNDO1

BC

Ben Cole

@brwcole · X

@RodrigoEstvez1 @miguelpinon_73 @aidanraneymd @HeartDrHanna @dngibson2 @joewalshmd The bleeding risk of apixiban was no worse than aspirin in Averoes https://t.co/YJi0MbhpfN